Epirubicin in patients with liver dysfunction: Development and evaluation of a novel dose modification scheme

European Journal of Cancer

Volumn 39, Issue 5, 2003, Pages 580-586

  Dobbs, N A ^a   Twelves, C J ^b   Gregory, W ^a   Cruickshanka, C ^b   Richards, M A ^a   Rubens, R D ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Breast Cancer; Chemotherapy; Epirubicin; Liver dysfunction; Pharmacokinetics

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BILIRUBIN; EPIRUBICIN; ANTINEOPLASTIC ANTIBIOTIC;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BIOCHEMISTRY; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INFECTION; LIVER FUNCTION TEST; LIVER METASTASIS; MAJOR CLINICAL STUDY; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; BLOOD; BREAST TUMOR; DRUG ADMINISTRATION; ENZYMOLOGY; EVALUATION; LIVER DISEASE; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; ASPARTATE AMINOTRANSFERASES; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; HUMANS; LIVER DISEASES; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0037334047     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00669-X     Document Type: Article

References (30)

1. Benjamin R.S., Wiernik P.H., Bachur N.R. Doxorubicin chemotherapy - efficacy and safety and pharmacologic basis of an intermittent single high-dosage schedule. Cancer. 33:1973;19-27.
2. Camagggi C.M., Strocchi E., Tamassia V.et al. Pharmacokinetic studies of 4′-Epi-Adriamycin in cancer patients with normal and impaired renal and with hepatic metastases. Cancer Treat Rep. 66:1982;1819-1824.
3. De Valeriola D. Dose optimization of anthracyclines. Anticancer Res. 14:1994;2307-2314.
4. Dobbs N.A., Twelves C.J. Anthracycline doses in patients with liver dysfunction. do UK oncologists follow current recommendations? Br J Cancer. 77:1998;1145-1148.
5. Dobbs N.A., Twelves C.J., Rizzi P.et al. Epirubicin in hepatocellular carcinoma. pharmacokinetics and clinical activity Cancer Chemother. Pharmacol. 34:1994;405-410.
6. Twelves C.J., Dobbs N.A., Michael Y.et al. Clinical pharmacokinetics of epirubicin. the importance of liver biochemistry tests Br. J. Cancer. 66:1992;765-769.
7. Dobbs N.A., Twelves C.J. What would be the effect of abandoning epirubicin dose adjustments for body surface area? Br. J. Cancer. 78:1998;662-666.
8. Handbook for Reporting Results of Cancer Treatment. 1979;World Health Organization, Geneva.
9. Hayward J.L., Carbone P., Heuson J.C.et al. Assessment of response to therapy in advanced breast cancer. Eur. J. Cancer. 13:1977;89-94.
10. Dobbs N.A., Twelves C.J. Measurement of epidoxorubicin and its metabolites by high-performance liquid chromatography using and advanced automated sample processor. J. Chromatogr. 572:1991;211-217.
11. Johnston A., Woollard R.C. Stripe. an interactive computer programme for the analysis of drug pharmacokinetics J. Pharmacol. Methods. 9:1983;193-200.
12. Schott B., Robert J. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture. Biochem. Pharmacol. 38:1989;4069-4074.
13. Twelves C.J., O'Reilly S.M., Coleman R.E., Richards M.A., Rubens R.D. Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry. Br. J. Cancer. 60:1989;938-941.
14. Twelves C.J., Richards M.A., Smith P., Rubens R.D. Epirubicin in breast cancer patients with liver metastases and abnormal liver biochemistry. initial weekly treatment followed by rescheduling and intensification Ann. Oncol. 2:1991;663-666.
15. Calvert A.H., Newell D.R., Gumbrell L.A. Carboplatin dosage. prospective evaluation of a simple formula based on renal function J. Clin. Oncol. 7:1989;1748-1756.
16. Camaggi C.M., Strocchi E., Comparsi R., Testoni F., Angelelli B., Pannuti F. Biliary excretion and pharmacokinetics of 4′epi-adriamycin (epirubicin) in advanced cancer patients. Cancer Chemother. Pharmacol. 18:1986;47-50.
17. Robert J., Vrignaud P., Nguyen-Ngoc T., Iliadis A., Mauriac L., Hurteloup P. Comparative phamacokinetics and metabolism of adriamycin and epidoxorubicin in patients with metastatic breast cancer. Cancer Treat. Rep. 69:1985;633-640.
18. Speth P.A.J., Linssen P.C.M., Beex L.V.A.M., Boezeman J.B.M., Haanen C. Cellular and plasma pharmacokinetics of weekly 20 mg 4′-epi-adriamycin bolus injection in patients with advanced breast cancer. Cancer Chemother. Pharmacol. 18:1986;78-82.
19. Bastholt L., Dalmark M., Gjedde S.B.et al. Dose response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer. a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group J. Clin. Oncol. 14:1996;1146-1155.
20. Jakobsen P., Basholt L., Dalmark M.et al. A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through a single blood sample measurement. Cancer Chemother. Pharmacol. 28:1991;465-468.
21. Ackland S.P., Ratain M., Vozelgang N.J., Choi K.E., Ruane M., Sinkule J.A. Pharmacokinetics and pharmacodynamics of long-term infusion of doxorubicin. Clin. Pharmacol. Ther. 45:1989;340-347.
22. Piscitelli S.C., Rodvold K.A., Rushing D.A., Tewksbury D.A. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin. Pharmacol. Ther. 191:1993;555-561.
23. Twelves C.J., Dobbs N.A., Lawrence M.A.et al. Iododoxorubicin in advanced breast cancer. a Phase II evaluation of clinical activity, pharmacology and quality of life Br. J. Cancer. 69:1994;726-731.
24. Hu O.Y.P., Chang S.P., Jane S.P., Chen K.Y. Pharmacokinetic and pharmacodynamic studies with 4′-epidoxorubicin in nasopharyngeal carcinoma patients. Cancer Chemother. Pharmacol. 24:1989;332-337.
25. Preisler H.D., Gessner T., Azarnia N.et al. Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute non-lymphocytic leukaemia. Cancer Chemother. Pharmacol. 12:1984;125-130.
26. Robert J., Illiadis A., Hoerni B., Cano J.-P., Durand M., Lagarde C. Pharmacokinetics of adriamycin in patients with breast cancer. correlation between pharmacokinetic parameters and clinical short-term response Eur. J. Cancer Clin. Oncol. 18:1982;739-745.
27. Wade J.R., Kelman A.W., Kerr D.J., Robert J., Whiting B. Variability in the pharmacokinetics of epirubicin. a population analysis Cancer Chemother. Pharmacol. 29:1992;391-395.
28. Dobbs N.A., Twelves C.J., Gillies H., James C.A., Harper P.G., Rubens R.D. Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother. Pharmacol. 36:1996;473-476.
29. Rodvold K.A., Rushin D.A., Tewksbury D.A. Doxorubicin clearance in the obese. J. Clin. Oncol. 6:1988;1321.
30. Richards M.A., Hopwood P., Ramirez A.J.et al. Doxorubicin in advanced breast cancer. influence of schedule on response, survival and quality of life Eur. J. Cancer. 28A:1992;1023-1028.